Wells Fargo & Company Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $144.00

Revolution Medicines (NASDAQ:RVMD) had its target price boosted by investment analysts at Wells Fargo & Company from $100.00 to $144.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price points to a potential upside of 43.25% from the stock’s previous close.

Other equities research analysts have also issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a research note on Thursday, January 22nd. Wolfe Research assumed coverage on shares of Revolution Medicines in a report on Tuesday, November 18th. They set an “outperform” rating and a $75.00 price target for the company. JPMorgan Chase & Co. boosted their price objective on shares of Revolution Medicines from $71.00 to $82.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Needham & Company LLC raised their target price on Revolution Medicines from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Finally, HC Wainwright boosted their price target on Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Five analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Revolution Medicines presently has an average rating of “Buy” and an average price target of $85.94.

Revolution Medicines Trading Down 2.6%

NASDAQ:RVMD traded down $2.72 during mid-day trading on Thursday, reaching $100.52. The company’s stock had a trading volume of 896,871 shares, compared to its average volume of 3,890,158. Revolution Medicines has a twelve month low of $29.17 and a twelve month high of $124.49. The company’s fifty day simple moving average is $98.19 and its two-hundred day simple moving average is $69.66. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.05 and a quick ratio of 8.05. The stock has a market cap of $19.43 billion, a P/E ratio of -19.58 and a beta of 1.01.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30). During the same period in the prior year, the firm earned ($1.12) EPS. On average, equities analysts predict that Revolution Medicines will post -3.49 EPS for the current year.

Insider Activity

In other Revolution Medicines news, COO Margaret A. Horn sold 75,000 shares of the business’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $100.56, for a total transaction of $7,542,000.00. Following the sale, the chief operating officer directly owned 141,053 shares in the company, valued at approximately $14,184,289.68. The trade was a 34.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Stephen Michael Kelsey sold 5,447 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $76.82, for a total transaction of $418,438.54. Following the completion of the transaction, the insider owned 278,600 shares of the company’s stock, valued at $21,402,052. This trade represents a 1.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 113,792 shares of company stock worth $10,734,640. 8.20% of the stock is owned by insiders.

Institutional Trading of Revolution Medicines

Several institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. lifted its holdings in Revolution Medicines by 1.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 10,066 shares of the company’s stock valued at $802,000 after acquiring an additional 125 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of Revolution Medicines by 0.4% in the fourth quarter. Deutsche Bank AG now owns 32,217 shares of the company’s stock valued at $2,566,000 after buying an additional 130 shares in the last quarter. Signaturefd LLC lifted its position in shares of Revolution Medicines by 33.1% during the 4th quarter. Signaturefd LLC now owns 656 shares of the company’s stock valued at $52,000 after acquiring an additional 163 shares during the last quarter. Allworth Financial LP boosted its stake in shares of Revolution Medicines by 57.2% during the 4th quarter. Allworth Financial LP now owns 577 shares of the company’s stock worth $46,000 after acquiring an additional 210 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its position in shares of Revolution Medicines by 44.7% during the fourth quarter. Farther Finance Advisors LLC now owns 751 shares of the company’s stock worth $60,000 after purchasing an additional 232 shares during the period. Institutional investors and hedge funds own 94.34% of the company’s stock.

More Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Evercore upgraded RVMD to a “strong-buy”, which can support near-term demand as investors re-rate the stock on growth potential and late‑stage assets. Zacks Evercore Upgrade
• Positive Sentiment: Media coverage highlights possible breakthrough signals in Revolution’s cancer programs, fueling optimism about future clinical readouts and commercial potential for RAS-addicted indications. Has Revolution Medicines Found a Breakthrough?
• Neutral Sentiment: Management will present at the TD Cowen 46th Annual Health Care Conference (CEO fireside chat on March 3), offering an opportunity for clarification on pipeline timing and strategy—watch for new timeline or data details. TD Cowen Participation
• Neutral Sentiment: Investor pieces discussing whether RVMD’s share price is “lagging” or mispriced could drive increased interest/flows but don’t change fundamentals by themselves. Is RVMD Share Price Lagging?
• Negative Sentiment: Zacks and the company’s release show Q4 EPS of ($1.86), a $0.30 miss vs. consensus, and management now expects 2026 operating expenses of $1.6B–$1.7B as it advances late‑stage RAS programs—this higher burn rate plus the earnings miss are the primary near-term drivers of selling pressure. RVMD Reports Wider-Than-Expected Q4 Loss
• Negative Sentiment: Company press release and MarketBeat note the EPS miss and year-over-year widening of losses; the increased cash burn raises financing and dilution risk until key trial readouts or partnerships materialize. Q4 and Full-Year 2025 Results

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.